Bioscript is a successful medical communications and regulatory writing agency for pharmaceutical companies. Sovereign has partnered with the management team to further develop and grow the business in this highly interesting and evolving market.
Bioscript is a successful global provider of medical communications and regulatory writing services for pharmaceutical companies. The business assists clients in their communications with regulatory authorities as well as educating the medical sector on pharmaceutical products that are in mid- to late-stage clinical trials and subsequently supporting these products, post market launch, to maintain and grow sales throughout the lifecycle of the drug.
Acquisitions to Date
Bioscript acquired two specialist global providers within 5 months of Sovereign's investment:
The Business Today
The acquisitions have strengthened Bioscript’s end-to-end service offering by extending the breadth and depth of its services across the pharmaceutical product lifecycle, and have brought additional capabilities in medical affairs, global market access strategy and payer value communications. The combined group has a staff of 135, which includes a large team of highly skilled specialist technical consultants and brings additional top 20 global pharma company clients.
Sovereign is working with the management team to further develop and grow the business.
Since partnering with Sovereign, we have been delighted with the M&A opportunities the team have brought and helped us to transact. The acquisitions will enable us to build upon our extensive, integrated services at a time when increasing trial complexity, regulatory demands and pricing pressures require a fully joined-up, cross-functional approach.
Andrew Medley / Founder & CEO / Bioscript